Advertisement
Advertisement
NAGE
Niagen Bioscience, Inc. Common Stock
2.15
USDSponsored
-0.13
-5.70%
Nov 10, 15:59 UTC -5
Closed
After-Market
2.17
+0.02
+1.16%
Niagen Bioscience, Inc. Common Stock (NAGE) Earnings
NAGE Earnings Reports
Positive Surprise Ratio
NAGE beat 23 of 40 last estimates.
57%
Next Report
Date of Next Report
Mar 02, 2027
Estimate for Q4 26 (Revenue/ EPS)
$30.53M
/-$0.01
Implied change from Q3 26 (Revenue/ EPS)
+12.28%
/-200.00%
Implied change from Q4 25 (Revenue/ EPS)
-9.78%
/-133.33%
Niagen Bioscience, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, NAGE reported earnings of 0.01 USD per share (EPS) for Q3 26, beating the estimate of 0.00 USD, resulting in a 488.24% surprise. Revenue reached 27.19 million, compared to an expected 31.30 million, with a -13.12% difference. The market reacted with a -16.47% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.01 USD, with revenue projected to reach 30.53 million USD, implying an decrease of -200.00% EPS, and increase of 12.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Niagen Bioscience, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Niagen Bioscience, Inc. Common Stock reported EPS of $0.01, beating estimates by 488.24%, and revenue of $27.19M, -13.12% below expectations.
How did the market react to Niagen Bioscience, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -16.47%, changed from $2.52 before the earnings release to $2.10 the day after.
When is Niagen Bioscience, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2027.
What are the forecasts for Niagen Bioscience, Inc. Common Stock's next earnings report?
Based on --
analysts, Niagen Bioscience, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $30.53M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.